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采用 CDR 移植技术对 mAb3D3 的重链可变区进行人源化。设计并通过重叠
PCR 技术构建出 hu3D3VH单域抗体基因。为了提高 hu3D3VH的功能性亲和力，
通过重组 PCR 技术分别将 SV5-Cys 基因和 p53 四聚化结构域基因与 hu3D3VH基





间接 ELISA 结果证实，单域抗体 hu3D3VH的抗原反应性和特异性与 3D3VH
基本相同。竞争 ELISA 结果证实，hu3D3VH 保留了单域抗体 3D3VH的抗原表位
特异性。流式细胞仪的分析结果显示，与 3D3VH 相比，hu3D3VH 的抗原结合能
力下降了约 29%；而与 hu3D3VH相比，dihu3D3VH 和 tehu3D3VH与靶抗原的结
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Humanization and Molecular downsizing of 
mAb3D3 against Human Lung Cancer 
Abstract 
Since the hybridoma technology was established, the monoclonal antibodies 
(mAbs) have been widely used in clinical diagnosis and therapies, owing to their 
excellent homogenicity, affinity and selectivity and so on. Unfortunately, the 
treatment outcomes of murine mAbs were heavily restricted because of its drawbacks 
in clinical therapies, such as causing the Human anti-Murine Antibody (HAMA) 
immune responses in human bodies and the feeble capacity of penetration because of 
large size molecules and so on. Following the development of molecular biology, the 
limitation of murine mAbs can be overcame by the humanization and molecular 
downsizing techniques, because the immunogenicity of murine mAbs was depressed 
and their pharmacokinetics characteristic was improved. The murine mAb3D3 against 
human lung cancer prepared by our lab was indicated that it would be promising on 
clinical application by a series of experimental studies in vivo and in vitro. To 
advance the clinical application of mAb3D3，the humanization  and molecular 
downsizing of mAb3D3 were performed in the dissertation. 
The heavy chain variable region of mAb3D3 was humanized by CDR grafting 
technique. The single-domain antibody hu3D3VH gene was designed, and constructed 
by overlapping PCR technique. To increase the functional affinity of hu3D3VH, the 
homogeneous dimer dihu3D3VH gene and tetramer tehu3D3VH gene were constructed 
by recombinant PCR technique, fusing the SV5-Cys gene and the p53 tetramerization 
domain gene to the hu3D3VH gene, respectively. The expression vectors pET-22b(+) 
/hu3D3VH, pET-22b(+)/dihu3D3VH and pET-22b(+)/tehu3D3VH were constructed, 
and expressed in E.coli BL21(DE3), respectively. They were all expressed mainly as 
inclusion bodies with the yield of more than 30% of total bacterial proteins. The 
expressed products were purified through Ni2+-affinity chromatographic column, 
respectively. After purification, the purity of the proteins were all more than 95%.  
The results of indirect ELISA confirmed that hu3D3VH remains the same 
reactivity and specificity of 3D3VH.  And the results of competitive ELISA 
confirmed that hu3D3VH remains the antigen epitope specificity of single-domain 
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combining with its antigens was decreased about 29% comparing with 3D3VH, and 
that the capacity of dihu3D3VH and tehu3D3VH combining with the target antigens 
were increased about 60% and 160% comparing with hu3D3VH, respectively.  
In summary, the high efficient prokaryotic expression system of humanized 
single-domain antibody hu3D3VH was built successfully. The prepared hu3D3VH 
remains the reactivity and specificity of parental antibody. And the homogeneous 
dimers and tetramers of hu3D3VH, which their functional affinity were both increased, 
were attained by genetic engineering technique. The studies of this dissertation lay the 
foundation for further analysis of their biological activity in vivo and in vitro, and for 
developing new targeted therapeutic agents of human lung cancer. 
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1.1.1  抗体研制的发展历程 








1.1.1.2  第二代抗体——单克隆抗体 







等已非常成熟。目前，mAb 的制备过程大致为[3]：①抗原免疫及 B 细胞的分离；
②细胞融合；③特异杂交瘤细胞的筛选；④杂交瘤细胞的克隆及建株；⑤杂交瘤
细胞的检定，包括染色体分析、抗体分泌稳定性分析、外源污染因子的检查等；
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捕获与相关抗原结合的抗体的 mRNA；以 mRNA 为模板，进行 RT-PCR 反应，
并重新引入 T7 启动子、SD 序列等核糖体展示必需元件，构建核糖体展示模板，
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性较少，而且在同一小鼠中不能产生IgG的各亚类，以及仍需要杂交瘤技术的常
规方法、存在专利权的限制等 [22,23]。 







表 1  美国 FDA 批准的抗体药物 
Table 1 Therapeutic monoclonal antibodies approved by the US FDA 
Generic name Trade name Sponsor company Type Approval date
Muromonab-CD3 Orthoclone Ortho Biotech Murine 1986 
Murine Mab(B72.3) OncoScint CYTOGEN Murine 1992 
Abciximab ReoPro Centocor Chimaeric 1994 
MurineMAb(PMSA) ProstaScint CYTOGEN Murine 1996 
Murine Fab´ fragment 
(Anti-CEA) CEA-Scan Immunomedics Murine 
1996 
T99 nofetumo mab 
merpentan Murine MAb Verluma DuPont Merck Murine 
1996 
Rituximab Rituxan Genentech Chimaeric 1997 
Daclizumab Zenapax Hoffman-La Roche Humanized 1997 
Basiliximab Simulect Novartis Chimaeric 1998 
Palivizumab Synagis Medlmmune Humanized 1998 
Infliximab Remicade Centocor Chimaeric 1998 
Trastuzumab Herceptin Genentech Humanized 1998 
Gemtuzumab Mylotarg Wyeth-Ayerst Humanized 2000 
Alemtuzumab Campath Millennium/ILEX Humanized 2001 
90Y-Ibritumomab Zevalin IDEC Murine 2002 
Infliximab Remicade Centocor Chimaeric 2002 
Adalimumab Humira Abbot Laboratories Humanized 2002 
LFA-3/IgG1 LFA-3 mAb Biogen Humanized 2003 
Tositumomab and Iodine 
I 131Tositumomab 
Bexxar Corixa Murine 2003 
omalizumab Xolair Novartis Humanized 2003 
cetuximab Erbitux Imclone Chimaeric 2004 
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图 1 抗体(IgG)的结构 
Fig. 1 The structure of antibody (IgG) 
A  The structure of complete antibody; B The structure of variable 
region of antibody. 
↓     ↓     ↓      ↓       ↓             ↓    ↓ 
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